查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1477998

人造器官和醫療仿生市場：依產品類型、最終用戶、地區 - 全球產業分析、規模、佔有率、成長、趨勢、預測，2024-2032 年

Artificial Vital Organs and Medical Bionics Market by Product Type, End-Users, and Geography : Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-20
出版日期: | 出版商: Persistence Market Research | 英文 306 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

這份研究報告對全球人造器官和醫學仿生市場進行了詳細的分析和解釋。這份綜合報告提供了有關主要市場趨勢、市場驅動因素、課題和新興趨勢的寶貴見解。它詳細概述了醫療保健行業的人造器官和醫療仿生學領域，並提供了獨家數據和統計數據來預測 2024 年至 2032 年的市場成長軌跡。

關鍵見解

  • 人造器官與醫療仿生市場規模（2024 年）：548 億美元
  • 預計市值（2032 年）：1,074 億美元
  • 全球市場成長率（2024-2032 年複合年增長率）：8.7%

人造器官和醫學仿生市場 - 報告範圍：

人造器官和醫療仿生市場包括各種人造器官、仿生設備和再生醫學解決方案，旨在替代或增強患者受損或失效的器官和組織的功能。該市場為醫療保健提供者、醫療設備製造商、生物技術公司以及患有器官衰竭、衰弱性損傷和慢性疾病的患者提供服務。人造器官和醫學仿生技術包括人工心臟、仿生肢體、人工耳蝸、視網膜植入物和組織工程器官。生物醫學工程、材料科學、再生醫學的進步以及器官衰竭、創傷和與年齡相關的退化性疾病盛行率的增加推動了市場成長。

市場驅動因素：

全球人造器官和醫學仿生學市場受益於幾個關鍵的市場驅動因素。人造器官、植入物和組織工程的技術進步使得能夠開發出更複雜、更實用的人造器官和仿生設備，並提高性能、耐用性和生物相容性。此外，對器官移植替代品、個人化醫療解決方案和患者特定植入物的需求不斷增長正在推動市場擴張。人造器官和醫學仿生學為末期器官衰竭和嚴重殘疾的患者提供了挽救生命和增強生命的選擇，提高了生活品質和長期結果。此外，支持性監管框架、政府資助措施和公私合作夥伴關係正在加速人造器官和醫學仿生技術的創新和市場引入。

市場限制因素：

雖然人造器官和醫療仿生學市場有望顯著成長，但它面臨著技術可接受性、成本效益和病患可及性方面的課題。仿生設備、外科手術和術後護理的高昂成本可能會限制市場滲透和患者的承受能力，特別是在衛生預算有限的低收入和中等收入國家。此外，移植手術的複雜性和侵入性，以及併發症和設備故障的風險，給患者接受和臨床醫生採用人造器官和醫學仿生技術帶來了課題。此外，倫理考量、社會恥辱以及對人體增強和增強的文化態度可能會影響患者和社會對仿生植入物和再生醫學治療的接受程度。解決這些障礙需要醫療保健利益相關者、產業合作夥伴和政策制定者共同努力，促進人造器官和仿生醫療技術的可近性、可負擔性和公平分配。

市場機會：

由於技術創新、以病人為中心的照護模式和市場擴張策略，人造器官和醫療仿生市場提供了巨大的成長機會。 3D 列印、奈米技術和生物電子醫學等新興趨勢為個人化製造、小型化以及仿生植入物和組織工程結構的整合提供了新途徑。生物混合器官、類器官和晶片器官平台的發展將進一步豐富藥物篩選、疾病建模和個人化治療所開發的生理和功能模型。此外，學術界、工業界和醫療保健提供者之間的策略合作將促進人造器官和醫學仿生技術的轉化研究、臨床試驗和商業化。此外，對病患教育、宣傳和支援服務的重視將提高人們對仿生植入物和再生醫學治療的認識、接受度和依從性。

本報告涵蓋的主要問題

  • 人造器官和醫學仿生市場的複合年增長率是多少？
  • 人造器官和醫療仿生市場的主要國家有哪些？
  • 人造器官和醫療仿生學市場的領先細分市場有哪些？
  • 到 2032 年，人造器官和醫療仿生學市場的成長預測是多少？
  • 哪些地區的人造器官和醫療仿生市場潛力最大？

競爭資訊與業務策略：

全球人造器官和醫療仿生市場的領先公司，包括醫療器材製造商、生技公司和學術研究機構，都致力於創新、協作和市場拓展，以獲得競爭優勢。這些公司投資研發，開發針對特定臨床適應症和患者群體的下一代人造器官、仿生設備和再生醫學治療方法。此外，與醫療保健提供者、患者倡導團體和監管機構的策略合作夥伴關係使公司能夠驗證產品的功效、安全性和市場適用性。此外，我們專注於以患者為中心的設計、使用者體驗和基於結果的報銷模式，在人造器官和醫學仿生學的競爭格局中提高患者滿意度和醫療保健價值。

公司主要簡介

  • SynCardia Systems, LLC
  • BiVACOR
  • CARMAT
  • Cleveland Heart
  • Jarvik Heart
  • MyLVAD
  • Thoratec Corporation
  • Abbott Diabetes
  • Asahi Kasei Medical Co. Ltd.
  • Edwards Lifesciences Corporation

人造器官與醫學仿生學市場研究細分：

依類型

  • 人造器官
  • 醫學仿生學

依地區

  • 北美
  • 拉丁美洲
  • 歐洲
  • 亞太地區
  • 中東/非洲

目錄

第 1 章執行摘要

第二章市場概述

  • 市場範圍/分類
  • 市場定義/範圍/限制

第三章市場風險與趨勢評估

  • 風險評估
    • COVID-19 危機及其對人工維生器官及醫學仿生學需求的影響
    • 與過去的危機相比，新冠肺炎 (COVID-19) 影響基準
    • 對市場價值的影響
    • 主要國家的評價
    • 依主要細分市場進行評估
    • 針對供應商的行動要點和建議
  • 影響市場的主要趨勢
  • 配方和產品開發的趨勢

第四章市場背景與基本資料點

  • 全球人造器官與醫學仿生市場
  • 人造器官與醫學仿生學市場機會評估
    • 市場總規模
    • 可服務且可尋址的市場
    • 可服務且可用的市場
  • 市場情境預測
    • 樂觀情況下的需求
    • 預期情況下的需求
    • 保守情境下的需求
  • 投資可行性分析
    • 投資成熟市場
      • 短期
      • 長期
    • 投資新興市場
      • 短期
      • 長期
  • 預測因子 - 相關性和影響
    • 主要公司的歷史成長
    • 全球人造器官和醫學仿生市場的成長
    • 人工器官與醫學仿生學引進率（依國家分列）
  • 市場動態
    • 市場驅動因素與影響評估
    • 主要市場課題與影響評估
    • 人造器官與醫學仿生學的市場機會
    • 世界市場的重要趨勢及其影響評估

第 5 章關鍵成功因素

  • 製造商專注於滲透率低但成長率高的市場
  • 押注該細分市場的高增量機會
  • 同業基準

第六章全球人造器官及醫學仿生市場需求分析

  • 過去的市場分析（2019-2023）
  • 目前與未來的市場預測（2024-2032 年）
  • 年成長趨勢分析

第七章全球人造器官及醫學仿生市場價值分析

  • 過往市值分析（2019-2023 年）
  • 目前與未來的市值預測（2024-2032 年）
    • 年成長趨勢分析
    • 絕對數量機會分析

第 8 章全球人造器官與醫療仿生市場分析：依類型

  • 簡介/主要發現
  • 過去的市場規模分析：依類型（2019-2023 年）
  • 當前和未來的市場規模分析和預測：依類型劃分（2024-2032 年）
    • 人工維生設備
    • 醫學仿生學
  • 依類型劃分的市場吸引力分析

第 9 章全球人造器官與醫療仿生市場分析：依地區

  • 簡介
  • 過去的市場規模分析：依地區劃分（2019-2023 年）
  • 目前與未來的市場規模分析與預測：依地區劃分（2024-2032 年）
    • 北美
    • 拉丁美洲
    • 歐洲
    • 亞太地區
    • 中東和非洲 (MEA)
  • 依地區劃分的市場吸引力分析

第十章北美人工器官及醫學仿生市場分析

第十一章拉丁美洲人工器官與醫學仿生市場分析

第十二章歐洲人造器官及醫學仿生市場分析

第十三章亞太地區人工器官及醫學仿生市場分析

第十四章中東及非洲人工器官及醫學仿生市場分析

第十五章：主要國家人工器官及醫學仿生市場分析

  • 簡介
    • 主要國家市值比例分析
    • 世界與國家成長比較
  • 美國人造器官與醫學仿生市場分析
    • 依市場分類進行價值比率分析
    • 依市場分類劃分的價值及分析與預測（2024-2032 年）
  • 加拿大人造器官與醫學仿生學市場分析
    • 依市場分類進行價值比率分析
    • 依市場分類劃分的價值及分析與預測（2024-2032 年）
  • 墨西哥人造器官與醫學仿生市場分析
    • 依市場分類進行價值比率分析
    • 依市場分類劃分的價值及分析與預測（2024-2032 年）
  • 巴西人造器官與醫學仿生市場分析
    • 依市場分類進行價值比率分析
    • 依市場分類劃分的價值及分析與預測（2024-2032 年）
  • 德國人造器官與醫學仿生市場分析
    • 依市場分類進行價值比率分析
    • 依市場分類劃分的價值及分析與預測（2024-2032 年）
  • 法國人造器官與醫學仿生市場分析
    • 依市場分類進行價值比率分析
    • 依市場分類劃分的價值及分析與預測（2024-2032 年）
  • 義大利人造器官與醫學仿生市場分析
    • 依市場分類進行價值比率分析
    • 依市場分類劃分的價值及分析與預測（2024-2032 年）
  • 比荷盧人造器官與醫學仿生學市場分析
    • 依市場分類進行價值比率分析
    • 依市場分類劃分的價值及分析與預測（2024-2032 年）
  • 英國人造器官與醫學仿生學市場分析
    • 依市場分類進行價值比率分析
    • 依市場分類劃分的價值及分析與預測（2024-2032 年）
  • 北歐國家人造器官與醫學仿生市場分析
    • 依市場分類進行價值比率分析
    • 依市場分類劃分的價值及分析與預測（2024-2032 年）
  • 中國人造器官及醫學仿生市場分析
    • 依市場分類進行價值比率分析
    • 依市場分類劃分的價值及分析與預測（2024-2032 年）
  • 日本人造器官與醫學仿生學市場分析
    • 依市場分類進行價值比率分析
    • 依市場分類劃分的價值及分析與預測（2024-2032 年）
  • 韓國人造器官與醫學仿生市場分析
    • 依市場分類進行價值比率分析
    • 依市場分類劃分的價值及分析與預測（2024-2032 年）
  • 海灣合作委員會國家人造器官與醫學仿生市場分析
    • 依市場分類進行價值比率分析
    • 依市場分類劃分的價值及分析與預測（2024-2032 年）
  • 南非人造器官與醫學仿生學市場分析
    • 依市場分類進行價值比率分析
    • 依市場分類劃分的價值及分析與預測（2024-2032 年）
  • 土耳其人造器官與醫學仿生學市場分析
    • 依市場分類進行價值比率分析
    • 依市場分類劃分的價值及分析與預測（2024-2032 年）
    • 國內競爭情勢及企業集中度

第十六章市場結構分析

  • 依公司層級進行市場分析
  • 市場集中度
  • 主要公司市佔率分析
  • 市場現況分析

第十七章競爭分析

  • 競爭對手儀表板
  • 競爭基準
  • 衝突詳情
    • SynCardia Systems, LLC
    • BiVACOR
    • CARMAT
    • Cleveland Heart
    • Jarvik Heart
    • MyLVAD
    • Thoratec Corporation
    • Abbott Diabetes
    • Asahi Kasei Medical Co. Ltd.
    • Edwards Lifesciences Corporation

第 18 章假設與縮寫

第十九章研究方法

簡介目錄
Product Code: PMRREP33106

Persistence Market Research, a renowned market research firm, has conducted an in-depth analysis of the global Artificial Vital Organs and Medical Bionics Market. This comprehensive report provides valuable insights into key market dynamics, growth drivers, challenges, and emerging trends. It offers a detailed overview of the artificial vital organs and medical bionics segment within the healthcare industry, presenting exclusive data and statistics projecting the market's growth trajectory from 2024 to 2032.

Key Insights:

  • Artificial Vital Organs and Medical Bionics Market Size (2024): USD54.8 Bn
  • Projected Market Value (2032): USD107.4 Bn
  • Global Market Growth Rate (CAGR 2024 to 2032):8.7%

Artificial Vital Organs and Medical Bionics Market - Report Scope:

The Artificial Vital Organs and Medical Bionics Market encompasses a wide range of artificial organs, bionic devices, and regenerative medicine solutions aimed at replacing or augmenting the function of damaged or failed organs and tissues in patients. This market serves healthcare providers, medical device manufacturers, biotechnology companies, and patients suffering from organ failure, debilitating injuries, or chronic diseases. Artificial vital organs and medical bionics technologies include artificial hearts, bionic limbs, cochlear implants, retinal prostheses, and tissue-engineered organs, among others. Market growth is driven by advancements in biomedical engineering, material science, and regenerative medicine, as well as increasing prevalence of organ failure, trauma injuries, and age-related degenerative disorders.

Market Growth Drivers:

The global Artificial Vital Organs and Medical Bionics Market benefits from several key growth drivers. Technological advancements in prosthetics, implants, and tissue engineering enable the development of more sophisticated and functional artificial organs and bionic devices with improved performance, durability, and biocompatibility. Moreover, increasing demand for organ transplantation alternatives, personalized medicine solutions, and patient-specific implants drives market expansion. Artificial vital organs and medical bionics offer life-saving and life-enhancing options for patients with end-stage organ failure or severe disabilities, improving their quality of life and long-term outcomes. Additionally, supportive regulatory frameworks, government funding initiatives, and public-private partnerships accelerate innovation and market adoption of artificial vital organs and medical bionics technologies.

Market Restraints:

Despite its significant growth prospects, the Artificial Vital Organs and Medical Bionics Market faces challenges related to technology acceptance, cost-effectiveness, and patient access. The high cost of bionic devices, surgical procedures, and postoperative care may limit market penetration and affordability for patients, particularly in low- and middle-income countries with constrained healthcare budgets. Moreover, the complexity and invasiveness of implantation procedures, as well as the risk of complications and device failures, pose challenges for patient acceptance and clinician adoption of artificial vital organs and medical bionics technologies. Furthermore, ethical considerations, social stigma, and cultural attitudes towards human enhancement and augmentation may influence patient and societal acceptance of bionic implants and regenerative medicine therapies. Addressing these barriers requires collaboration between healthcare stakeholders, industry partners, and policymakers to promote access, affordability, and equitable distribution of artificial vital organs and medical bionics technologies.

Market Opportunities:

The Artificial Vital Organs and Medical Bionics Market presents significant growth opportunities driven by technological innovations, patient-centered care models, and market expansion strategies. Emerging trends such as 3D printing, nanotechnology, and bioelectronic medicine offer new avenues for personalized fabrication, miniaturization, and integration of bionic implants and tissue-engineered constructs. The development of biohybrid organs, organoids, and organ-on-a-chip platforms enables more physiological and functional models for drug screening, disease modeling, and personalized therapy development. Moreover, strategic collaborations between academia, industry, and healthcare providers facilitate translational research, clinical trials, and commercialization of artificial vital organs and medical bionics technologies. Furthermore, emphasis on patient education, advocacy, and support services enhances awareness, acceptance, and adherence to bionic implants and regenerative medicine therapies.

Key Questions Answered in the Report:

  • What is the CAGR of the Artificial Vital Organs And Medical Bionics Market?
  • Which is the Leading Country in the Artificial Vital Organs And Medical Bionics Market?
  • Which Segment Leads in the Artificial Vital Organs And Medical Bionics Market by Type?
  • What is the Growth Estimated for the Artificial Vital Organs And Medical Bionics Market by 2032?
  • Which Region has the highest potential in the Artificial Vital Organs And Medical Bionics Market?

Competitive Intelligence and Business Strategy:

Leading players in the global Artificial Vital Organs and Medical Bionics Market, including medical device manufacturers, biotechnology companies, and academic research institutions, focus on innovation, collaboration, and market expansion to gain a competitive edge. These companies invest in research and development to develop next-generation artificial organs, bionic devices, and regenerative medicine therapies tailored to specific clinical indications and patient populations. Moreover, strategic partnerships with healthcare providers, patient advocacy groups, and regulatory agencies enable companies to validate product efficacy, safety, and market readiness. Furthermore, emphasis on patient-centered design, user experience, and outcomes-based reimbursement models enhances patient satisfaction and healthcare value in the competitive landscape of artificial vital organs and medical bionics.

Key Companies Profiled:

  • SynCardia Systems, LLC
  • BiVACOR
  • CARMAT
  • Cleveland Heart
  • Jarvik Heart
  • MyLVAD
  • Thoratec Corporation
  • Abbott Diabetes
  • Asahi Kasei Medical Co. Ltd.
  • Edwards Lifesciences Corporation

Artificial Vital Organs and Medical Bionics Market Research Segmentation:

By Type

  • Artificial Vital Organs
  • Medical Bionics

By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Summary of Statistics
  • 1.3. Key Market Characteristics & Attributes
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations

3. Market Risks and Trends Assessment

  • 3.1. Risk Assessment
    • 3.1.1. COVID-19 Crisis and Impact on Artificial Vital Organs And Medical Bionics Demand
    • 3.1.2. COVID-19 Impact Benchmark with Previous Crisis
    • 3.1.3. Impact on Market Value (US$ Mn)
    • 3.1.4. Assessment by Key Countries
    • 3.1.5. Assessment by Key Market Segments
    • 3.1.6. Action Points and Recommendation for Suppliers
  • 3.2. Key Trends Impacting the Market
  • 3.3. Formulation and Product Development Trends

4. Market Background and Foundation Data Points

  • 4.1. Global Artificial Vital Organs And Medical Bionics Market (US$ Mn)
  • 4.2. Artificial Vital Organs And Medical Bionics Market Opportunity Assessment (US$ Mn)
    • 4.2.1. Total Available Market
    • 4.2.2. Serviceable Addressable Market
    • 4.2.3. Serviceable Obtainable Market
  • 4.3. Market Scenario Forecast
    • 4.3.1. Demand in optimistic Scenario
    • 4.3.2. Demand in Likely Scenario
    • 4.3.3. Demand in Conservative Scenario
  • 4.4. Investment Feasibility Analysis
    • 4.4.1. Investment in Established Markets
      • 4.4.1.1. In Short Term
      • 4.4.1.2. In Long Term
    • 4.4.2. Investment in Emerging Markets
      • 4.4.2.1. In Short Term
      • 4.4.2.2. In Long Term
  • 4.5. Forecast Factors - Relevance & Impact
    • 4.5.1. Top Companies Historical Growth
    • 4.5.2. Global Artificial Vital Organs And Medical Bionics Market Growth
    • 4.5.3. Artificial Vital Organs And Medical Bionics Adoption Rate, by Country
  • 4.6. Market Dynamics
    • 4.6.1. Market Driving Factors and Impact Assessment
    • 4.6.2. Prominent Market Challenges and Impact Assessment
    • 4.6.3. Artificial Vital Organs And Medical Bionics Market Opportunities
    • 4.6.4. Prominent Trends in the Global Market & Their Impact Assessment

5. Key Success Factors

  • 5.1. Manufacturers' Focus on Low Penetration High Growth Markets
  • 5.2. Banking on with Segments High Incremental Opportunity
  • 5.3. Peer Benchmarking

6. Global Artificial Vital Organs And Medical Bionics Market Demand Analysis 2019-2023 and Forecast, 2024-2032

  • 6.1. Historical Market Analysis, 2019-2023
  • 6.2. Current and Future Market Projections, 2024-2032
  • 6.3. Y-o-Y Growth Trend Analysis

7. Global Artificial Vital Organs And Medical Bionics Market Value Analysis 2019-2023 and Forecast, 2024-2032

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2032
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Artificial Vital Organs And Medical Bionics Market Analysis 2019-2023 and Forecast 2024-2032, By Type

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis By Type, 2019-2023
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Type, 2024-2032
    • 8.3.1. Artificial Vital Organs
    • 8.3.2. Medical Bionics
  • 8.4. Market Attractiveness Analysis By Type

9. Global Artificial Vital Organs And Medical Bionics Market Analysis 2019-2023 and Forecast 2024-2032, By Region

  • 9.1. Introduction
  • 9.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
  • 9.3. Current Market Size (US$ Mn) & Analysis and Forecast By Region, 2024-2032
    • 9.3.1. North America
    • 9.3.2. Latin America
    • 9.3.3. Europe
    • 9.3.4. Asia Pacific
    • 9.3.5. Middle East and Africa (MEA)
  • 9.4. Market Attractiveness Analysis By Region

10. North America Artificial Vital Organs And Medical Bionics Market Analysis 2019-2023 and Forecast 2024-2032

  • 10.1. Introduction
  • 10.2. Pricing Analysis
  • 10.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 10.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2024-2032
    • 10.4.1. By Country
      • 10.4.1.1. U.S.
      • 10.4.1.2. Canada
    • 10.4.2. By Type
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Country
    • 10.5.2. By Type

11. Latin America Artificial Vital Organs And Medical Bionics Market Analysis 2019-2023 and Forecast 2024-2032

  • 11.1. Introduction
  • 11.2. Pricing Analysis
  • 11.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 11.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2024-2032
    • 11.4.1. By Country
      • 11.4.1.1. Brazil
      • 11.4.1.2. Mexico
      • 11.4.1.3. Rest of Latin America
    • 11.4.2. By Type
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Country
    • 11.5.2. By Type

12. Europe Artificial Vital Organs And Medical Bionics Market Analysis 2019-2023 and Forecast 2024-2032

  • 12.1. Introduction
  • 12.2. Pricing Analysis
  • 12.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 12.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2024-2032
    • 12.4.1. By Country
      • 12.4.1.1. Germany
      • 12.4.1.2. France
      • 12.4.1.3. U.K.
      • 12.4.1.4. Italy
      • 12.4.1.5. Benelux
      • 12.4.1.6. Nordic Countries
      • 12.4.1.7. Rest of Europe
    • 12.4.2. By Type
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Country
    • 12.5.2. By Type

13. Asia Pacific Artificial Vital Organs And Medical Bionics Market Analysis 2019-2023 and Forecast 2024-2032

  • 13.1. Introduction
  • 13.2. Pricing Analysis
  • 13.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 13.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2024-2032
    • 13.4.1. By Country
      • 13.4.1.1. China
      • 13.4.1.2. Japan
      • 13.4.1.3. South Korea
      • 13.4.1.4. Rest of Asia Pacific
    • 13.4.2. By Type
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Country
    • 13.5.2. By Type

14. Middle East and Africa Artificial Vital Organs And Medical Bionics Market Analysis 2019-2023 and Forecast 2024-2032

  • 14.1. Introduction
  • 14.2. Pricing Analysis
  • 14.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 14.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2024-2032
    • 14.4.1. By Country
      • 14.4.1.1. GCC Countries
      • 14.4.1.2. South Africa
      • 14.4.1.3. Turkey
      • 14.4.1.4. Rest of Middle East and Africa
    • 14.4.2. By Type
  • 14.5. Market Attractiveness Analysis
    • 14.5.1. By Country
    • 14.5.2. By Type

15. Key Countries Artificial Vital Organs And Medical Bionics Market Analysis 2019-2023 and Forecast 2024-2032

  • 15.1. Introduction
    • 15.1.1. Market Value Proportion Analysis, By Key Countries
    • 15.1.2. Global Vs. Country Growth Comparison
  • 15.2. US Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.2.1. Value Proportion Analysis by Market Taxonomy
    • 15.2.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.2.2.1. By Type
  • 15.3. Canada Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.3.1. Value Proportion Analysis by Market Taxonomy
    • 15.3.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.3.2.1. By Type
  • 15.4. Mexico Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.4.1. Value Proportion Analysis by Market Taxonomy
    • 15.4.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.4.2.1. By Type
  • 15.5. Brazil Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.5.1. Value Proportion Analysis by Market Taxonomy
    • 15.5.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.5.2.1. By Type
  • 15.6. Germany Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.6.1. Value Proportion Analysis by Market Taxonomy
    • 15.6.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.6.2.1. By Type
  • 15.7. France Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.7.1. Value Proportion Analysis by Market Taxonomy
    • 15.7.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.7.2.1. By Type
  • 15.8. Italy Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.8.1. Value Proportion Analysis by Market Taxonomy
    • 15.8.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.8.2.1. By Type
  • 15.9. BENELUX Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.9.1. Value Proportion Analysis by Market Taxonomy
    • 15.9.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.9.2.1. By Type
  • 15.10. UK Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.10.1. Value Proportion Analysis by Market Taxonomy
    • 15.10.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.10.2.1. By Type
  • 15.11. Nordic Countries Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.11.1. Value Proportion Analysis by Market Taxonomy
    • 15.11.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.11.2.1. By Type
  • 15.12. China Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.12.1. Value Proportion Analysis by Market Taxonomy
    • 15.12.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.12.2.1. By Type
  • 15.13. Japan Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.13.1. Value Proportion Analysis by Market Taxonomy
    • 15.13.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.13.2.1. By Type
  • 15.14. South Korea Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.14.1. Value Proportion Analysis by Market Taxonomy
    • 15.14.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.14.2.1. By Type
  • 15.15. GCC Countries Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.15.1. Value Proportion Analysis by Market Taxonomy
    • 15.15.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.15.2.1. By Type
  • 15.16. South Africa Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.16.1. Value Proportion Analysis by Market Taxonomy
    • 15.16.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.16.2.1. By Type
  • 15.17. Turkey Artificial Vital Organs And Medical Bionics Market Analysis
    • 15.17.1. Value Proportion Analysis by Market Taxonomy
    • 15.17.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
      • 15.17.2.1. By Type
    • 15.17.3. Competition Landscape and Player Concentration in the Country

16. Market Structure Analysis

  • 16.1. Market Analysis by Tier of Companies
  • 16.2. Market Concentration
  • 16.3. Market Share Analysis of Top Players
  • 16.4. Market Presence Analysis
    • 16.4.1. By Regional footprint of Players
    • 16.4.2. Product footprint by Players

17. Competition Analysis

  • 17.1. Competition Dashboard
  • 17.2. Competition Benchmarking
  • 17.3. Competition Deep Dive
    • 17.3.1. SynCardia Systems, LLC
      • 17.3.1.1. Overview
      • 17.3.1.2. Product Portfolio
      • 17.3.1.3. Sales Footprint
      • 17.3.1.4. Strategy Overview
    • 17.3.2. BiVACOR
      • 17.3.2.1. Overview
      • 17.3.2.2. Product Portfolio
      • 17.3.2.3. Sales Footprint
      • 17.3.2.4. Strategy Overview
    • 17.3.3. CARMAT
      • 17.3.3.1. Overview
      • 17.3.3.2. Product Portfolio
      • 17.3.3.3. Sales Footprint
      • 17.3.3.4. Strategy Overview
    • 17.3.4. Cleveland Heart
      • 17.3.4.1. Overview
      • 17.3.4.2. Product Portfolio
      • 17.3.4.3. Sales Footprint
      • 17.3.4.4. Strategy Overview
    • 17.3.5. Jarvik Heart
      • 17.3.5.1. Overview
      • 17.3.5.2. Product Portfolio
      • 17.3.5.3. Sales Footprint
      • 17.3.5.4. Strategy Overview
    • 17.3.6. MyLVAD
      • 17.3.6.1. Overview
      • 17.3.6.2. Product Portfolio
      • 17.3.6.3. Sales Footprint
      • 17.3.6.4. Strategy Overview
    • 17.3.7. Thoratec Corporation
      • 17.3.7.1. Overview
      • 17.3.7.2. Product Portfolio
      • 17.3.7.3. Sales Footprint
      • 17.3.7.4. Strategy Overview
    • 17.3.8. Abbott Diabetes
      • 17.3.8.1. Overview
      • 17.3.8.2. Product Portfolio
      • 17.3.8.3. Sales Footprint
      • 17.3.8.4. Strategy Overview
    • 17.3.9. Asahi Kasei Medical Co. Ltd.
      • 17.3.9.1. Overview
      • 17.3.9.2. Product Portfolio
      • 17.3.9.3. Sales Footprint
      • 17.3.9.4. Strategy Overview
    • 17.3.10. Edwards Lifesciences Corporation
      • 17.3.10.1. Overview
      • 17.3.10.2. Product Portfolio
      • 17.3.10.3. Sales Footprint
      • 17.3.10.4. Strategy Overview

18. Assumptions and Acronyms Used

19. Research Methodology